For instance, therapies that could achieve ghrelin cell–selective IR blockade would presumably help protect against insulin-induced hypoglycemia (by preventing insulin-induced drops in ghrelin) without gains in body weight, which are often considered unwelcome. This evidence concerns the gene GHRL and Hypoglycemia.